top of page

Juniper IP Dictionary

Writer's picture: Juniper IPJuniper IP

Let's take a look at some of the terms of intellectual property.



Machine Learning Model Protection

Machine Learning Model Protection refers to the safeguarding of machine learning models, which are increasingly becoming valuable intellectual property in AI technology. These models use data-driven algorithms and mathematical methods to perform various tasks. Intellectual property rights can be granted to protect these models, preventing others from using them without permission. Protection mechanisms could include patents, trade secrets, and other legal instruments to secure the commercial potential of these AI models.


AI Patent Thickets

AI Patent Thickets refer to a situation where numerous patents covering similar technologies accumulate in a particular field, such as artificial intelligence. This dense cluster of patents can make it difficult for innovators to develop new solutions without infringing on existing patents. In the AI sector, patent thickets can limit the implementation of new technologies, particularly for startups or smaller companies that may struggle with patent-related challenges. The dense nature of these patent clusters can create barriers to entry in the market.


Intangible Asset Valuation

Intangible Asset Valuation is the process of determining the financial value of intangible assets, such as intellectual property, which can have a significant impact on a company’s overall value. These assets can include trademarks, patents, copyrights, trade secrets, and software. The valuation of these assets depends on factors such as their commercial potential, market share, and the innovative capacity of the company. Intangible asset valuation is critical for investors, as it helps assess a company’s true worth beyond tangible physical assets.


Orphan Drug Exclusivity

Orphan Drug Exclusivity refers to the exclusive market rights granted to pharmaceutical companies for drugs developed to treat rare diseases, which affect a small number of patients. These rights are typically granted for a specific period, allowing the manufacturer to be the sole producer and distributor of the drug during that time. This exclusivity period serves as an incentive for companies to develop drugs for rare diseases by offering protection against competition, making it financially viable for them to invest in research and development.


Compulsory Licensing

Compulsory Licensing is a practice where governments or authorized bodies mandate the owner of intellectual property, usually a patent, to grant a license to another party under specific conditions. This is often applied in situations where public health needs or national emergencies require the production or distribution of a product that the patent holder may not make available at affordable prices. In the pharmaceutical sector, compulsory licensing is frequently invoked during health crises, enabling wider access to essential medicines in low-income or crisis-stricken regions.


0 views0 comments

Comments


bottom of page